Researchers at the Johnson & Johnson Pharmaceutical Research & Development, New Jersey and Belgium, and University of California, Los Angeles, CA used the Cambridge Neuropsychological Test Automated Battery (CANTAB) and cognitive adverse events to evaluate neurocognitive effects of topiramate 100 mg/day vs placebo in 70 migraine patients aged 12 through 17 years
INTRODUCTION: Migraine is a very common medical disorder characterized by attacks of moderate-severe...
The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at t...
We reviewed the electronic records of 74 migraine patients treated with topiramate for more than 6 w...
This paper reviews the clinical implications of topiramate (TPM)-induced cognitive deficits in patie...
Few data are available on cognitive and psychiatric effects of topiramate (TPM) monotherapy in migra...
Migraine is the sixth most common cause of disability in the world. Preventive migraine treatment is...
Abstract Background Topiramate is approved for the prophylaxis (prevention) of migraine headache in ...
Topiramate is a newer drug with a strong antiepileptic potential, but also with adverse effects, esp...
Migraine headaches are typically episodic in nature and may affect nearly 10% of the population. In ...
We studied the excitability of the visual and motor cortex in 36 patients with frequent migraine wit...
Introduction/Objective. The aim of this follow-up study was to determine the effects of topiramate t...
To compare adverse drug reactions (ADRs) to topiramate in patients with migraine and patients with e...
Investigators at the Universities of Minnesota and Florida determined the effect of topiramate on li...
Topiramate is an antiepileptic drug that has marked treatment-limiting side effects on specific aspe...
The effects of topiramate (TPA) adjunctive therapy on cognition in 22 consecutive patients with intr...
INTRODUCTION: Migraine is a very common medical disorder characterized by attacks of moderate-severe...
The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at t...
We reviewed the electronic records of 74 migraine patients treated with topiramate for more than 6 w...
This paper reviews the clinical implications of topiramate (TPM)-induced cognitive deficits in patie...
Few data are available on cognitive and psychiatric effects of topiramate (TPM) monotherapy in migra...
Migraine is the sixth most common cause of disability in the world. Preventive migraine treatment is...
Abstract Background Topiramate is approved for the prophylaxis (prevention) of migraine headache in ...
Topiramate is a newer drug with a strong antiepileptic potential, but also with adverse effects, esp...
Migraine headaches are typically episodic in nature and may affect nearly 10% of the population. In ...
We studied the excitability of the visual and motor cortex in 36 patients with frequent migraine wit...
Introduction/Objective. The aim of this follow-up study was to determine the effects of topiramate t...
To compare adverse drug reactions (ADRs) to topiramate in patients with migraine and patients with e...
Investigators at the Universities of Minnesota and Florida determined the effect of topiramate on li...
Topiramate is an antiepileptic drug that has marked treatment-limiting side effects on specific aspe...
The effects of topiramate (TPA) adjunctive therapy on cognition in 22 consecutive patients with intr...
INTRODUCTION: Migraine is a very common medical disorder characterized by attacks of moderate-severe...
The objectives of this paper are to evaluate the efficacy and tolerability of topiramate, given at t...
We reviewed the electronic records of 74 migraine patients treated with topiramate for more than 6 w...
DOI
Add to ORKG